EUCTR2015-003105-41-GB进行中（未招募）1 期
CNS Unmet Medical Need in Mucopolysaccharidosis: A Phase 2 Safety and Pharmacokinetics Study of Ataluren (COMPASS) - COMPASS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Evidence of signed and dated informed consent document(s) indicating that the study candidate (and/or a parent/legal guardian) has been informed of all pertinent aspects of the study. Note: If the study candidate is considered a child under local regulation, a parent or legal guardian must provide written consent prior to initiation of study screening procedures and the study candidate may be required to provide written assent. The rules of the responsible institutional review board/independent ethics committee (IRB/IEC) regarding whether one or both parents must provide consent and the appropriate ages for obtaining consent and assent from the patient should be followed.
- •2.Age =2 years.
- •3.Clinical diagnosis of MPS I, confirmed by measurable clinical signs and symptoms of MPS I and a fibroblast or leukocyte a-L-iduronidase enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory, with clinically stable disease.
- •4.Documentation of the presence of a nonsense mutation in at least 1 allele of the a-L-iduronidase (IDUA) gene.
- •5.Verification that a blood sample has been drawn for confirmation of the presence of a nonsense mutation in the IDUA gene.
- •6.Confirmed screening laboratory values within the central laboratory ranges
- •7. In patients who are sexually active, willingness, if not surgically sterile, to abstain from
- •sexual intercourse or employ a barrier or medical method of contraception during ataluren
- •administration and for 60 days after the last ataluren administration.
- •8. Willingness and ability to comply with scheduled visits, drug administration plan, study
- •procedures (including lumbar punctures), and study restrictions.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 4
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any change (initiation, change in type of drug, dose modification [not weight based], schedule modification, interruption, discontinuation, or re-initiation) in ERT within 6 months prior to start of screening.
- •2. Exposure to another investigational drug or (intrathecal/spinal) device within 3 months prior to enrollment.
- •3. Ongoing participation in any other therapeutic clinical trial.
- •4.The patient is unable to have a lumbar puncture performed due to severe musculoskeletal/spinal abnormalities, risk of abnormal bleeding, or the presence of a ventriculoperitoneal shunt.
- •5. The patient is unable to provide a CSF sample due to an opening CSF pressure that exceeds 30.0 cm H2O.
- •6. The patient has any known or suspected hypersensitivity to anesthesia that is thought to be by a physician or anesthesiologist as an unacceptably high risk for anesthesia due to compromised airways or other conditions.
- •7. Is pregnant or lactating. Female patients of childbearing potential must have a negative pregnancy test [ß-human chronic gonadotropin (hCG)] at screening.
- •8. Ongoing use of the following drugs:
- •Drugs metabolized by CYP2C8 (eg, paclitaxel) or CYP2C9 (eg, coumarin anticoagulants [warfarin], phenytoin or tolbutamide)
- •Drugs that are inhibitors of breast cancer resistant protein (BCRP) (eg, cyclosporine, eltrombopag, geftinib). Note: Topical cyclosporine therapy is permitted.
- •Drugs that are substrates of UGT1A9 (eg, propofol, mycophenolate mofetil), OAT1, OAT3, or OATP1B3 (eg, oseltamivir, acyclovir, captopril, furosemide, bumetanide, valsartan, pravastatin, rosuvastatin, atorvastatin, pitavastatin)
- •Drugs that are general inhibitors of UGT (eg, probenecid, valproic acid)
- •9. Ongoing IV aminoglycoside use.
- •10. Prior or ongoing medical condition (eg, concomitant illness, alcoholism, drug abuse, psychiatric condition), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator’s opinion, could adversely affect the safety of the patient, makes it unlikely that the course of study drug administration or follow-up would be completed, or could impair the assessment of study results.
- •11. Known hypersensitivity to any of the ingredients or excipients of the study drug (polydextrose, polyethylene glycol 3350, poloxamer 407, mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, vanilla, colloidal silica, or magnesium stearate).
- •12. Surgery within 30 days prior to enrollment, or anticipated surgery during study participation
研究者
相似试验
已完成
不适用
A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)Mucopolysaccharidosis Type IIIBMucopolysaccharidosis Type 3 BMPS III BMPS 3 BNCT02493998Allievex Corporation22
已完成
不适用
Core Outcome Set for Head, Neck and Respiratory Disease in Mucopolysaccharidosis IIMucopolysaccharidosis Type IINCT06022380Manchester University NHS Foundation Trust46
已完成
2 期
A Study in MPS VI to Assess Safety and Efficacy of OdiparcilMucopolysaccharidosis VINCT03370653Inventiva Pharma20
已完成
不适用
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in MucopolysaccharidosisMucopolysaccharidosesNCT04112602University Hospital, Tours27
已完成
不适用
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip DiseaseMucopolysaccharidosis IV AMucopolysaccharidosis VINCT01707433Children's Hospitals and Clinics of Minnesota22